NanoString Technologies Stock Price, Forecast & Analysis (NASDAQ:NSTG)

NanoString Technologies trades on the NASDAQ under the ticker symbol "NSTG."

NanoString Technologies Inc (NASDAQ:NSTG) issued its earnings results on Monday, November, 4th. The biotechnology company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.54) by $0.10. The biotechnology company had revenue of $30.60 million for the quarter, compared to analyst estimates of $28.05 million. NanoString Technologies had a negative return on equity of 118.32% and a negative net margin of 72.30%. View NanoString Technologies' Earnings History.

NanoString Technologies is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for NanoString Technologies.

1 equities research analysts have issued 12 month target prices for NanoString Technologies' stock. Their forecasts range from $35.00 to $35.00. On average, they expect NanoString Technologies' share price to reach $35.00 in the next twelve months. This suggests a possible upside of 48.9% from the stock's current price. View Analyst Price Targets for NanoString Technologies.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NanoString Technologies in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for NanoString Technologies.

Media coverage about NSTG stock has been trending somewhat positive recently, according to InfoTrie Sentiment. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. NanoString Technologies earned a coverage optimism score of 1.7 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for NanoString Technologies.

Some companies that are related to NanoString Technologies include Iovance Biotherapeutics (IOVA), Crispr Therapeutics (CRSP), Halozyme Therapeutics (HALO), Acceleron Pharma (XLRN), Momenta Pharmaceuticals (MNTA), Regenxbio (RGNX), Denali Therapeutics (DNLI), Coherus Biosciences (CHRS), Audentes Therapeutics (BOLD), Alector (ALEC), Orchard Therapeutics (ORTX), Sangamo Therapeutics (SGMO), Fate Therapeutics (FATE), Editas Medicine (EDIT) and Aerie Pharmaceuticals (AERI).

Based on aggregate information from My MarketBeat watchlists, some companies that other NanoString Technologies investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Aegean Marine Petroleum Network (ANW), Chipotle Mexican Grill (CMG), Precision Drilling (PD), AutoZone (AZO), Bank Of The Ozarks (OZRK), Designer Brands (DBI) and Eaton Vance Floating-Rate Income Trust (EFT).

NanoString Technologies' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (11.05%), Nikko Asset Management Americas Inc. (11.02%), Rhenman & Partners Asset Management AB (0.40%), Fisher Asset Management LLC (0.38%), California Public Employees Retirement System (0.24%) and State of New Jersey Common Pension Fund D (0.22%). Company insiders that own NanoString Technologies stock include Charles P Waite, Jr, David W Ghesquiere, K Thomas Bailey, Kirk Malloy, Lifesciences Ii LP Clarus, Mary Tedd Allen, Nicholas Galakatos, R Bradley Gray and William Young. View Institutional Ownership Trends for NanoString Technologies.

NSTG stock was sold by a variety of institutional investors in the last quarter, including Columbus Circle Investors, Russell Investments Group Ltd., Strs Ohio, First Mercantile Trust Co. and Conestoga Capital Advisors LLC. Company insiders that have sold NanoString Technologies company stock in the last year include Charles P Waite, Jr, David W Ghesquiere, K Thomas Bailey, Kirk Malloy, Lifesciences Ii LP Clarus, Mary Tedd Allen, R Bradley Gray and William Young. View Insider Buying and Selling for NanoString Technologies.

NSTG stock was purchased by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Fisher Asset Management LLC, State of New Jersey Common Pension Fund D, SG Americas Securities LLC, California Public Employees Retirement System, Rhenman & Partners Asset Management AB and Truvestments Capital LLC. View Insider Buying and Selling for NanoString Technologies.

Shares of NSTG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NSTG stock can currently be purchased for approximately $23.51.

NanoString Technologies has a market capitalization of $840.20 million and generates $106.73 million in revenue each year. The biotechnology company earns $-77,400,000.00 in net income (profit) each year or ($2.78) on an earnings per share basis. NanoString Technologies employs 476 workers across the globe.View Additional Information About NanoString Technologies.

The official website for NanoString Technologies is http://www.nanostring.com/.

NanoString Technologies' mailing address is 530 FAIRVIEW AVENUE NORTH SUITE 2000, SEATTLE WA, 98109. The biotechnology company can be reached via phone at 206-378-6266 or via email at [email protected]